Official funding announcement — preliminary draft
Funder: National Institutes of Health
Opportunity number: PAR-28-072
Official listed status: posted
Closing information: 2029-11-16 (official deadline clock time and time zone must be checked in NOFO)
Award disclosure: Applicant-level ceiling not stated in the retrieved federal synopsis; verify in full NOFO.
Applicant categories in federal synopsis: Independent school districts; Small businesses; Public housing authorities/Indian housing authorities; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Others (see text field entitled "Additional Information on Eligibility" for clarification); City or township governments; Private institutions of higher education; County governments; Native American tribal organizations (other than Federally recognized tribal governments); For profit organizations other than small businesses; State governments; Public and State controlled institutions of higher education; Native American tribal governments (Federally recognized); Special district governments
Federal synopsis
The purpose of NEI's Translational Research program (TRP) is the rapid and efficient translation of innovative laboratory research findings into therapeutics for use by clinicians to treat visual system diseases or disorders. The TRP will support the product development of biological, pharmaceutical, medical device, and/or combination therapies for any disease or disorder of the visual system.The TRP will utilize a bi-phasic, milestone-driven mechanism of award. The R61 phase can be up to two years and will support research that has demonstrated significant preliminary data but has not advanced to the level of clinical translation. The R33 phase can be up to four years and will support research that is in the final states of preclinical development with potential for near-term clinical development. The total duration of both R61 and R33 cannot exceed five years. The R33 is to focus on advancing a single therapeutic candidate through Investigational New Drug or Investigational Device Exemption (IND/IDE) enabling studies, filing an IND/IDE package with the FDA, and designing future clinical trials. R33 recipients must submit or obtain an IND/IDE application to FDA, or must transition the product to clinical practice, within the period of performance. The specific activities appropriate for the R33 phase will depend on the product under study and available preliminary data on the product. Delineation of milestones by the applicant for the R61 and R33 phases is a key characteristic …
Draft intake record. Eligibility, program terms, current amendments and applicant ceiling must be independently verified before publishing.